Rosiglitazone and implications for pharmacovigilance.
Kazi
Dhruv
D
D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D015201:Meta-Analysis as Topic; D011358:Product Surveillance, Postmarketing; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects*; D014481:United States; D014486:United States Food and Drug Administration
D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone